FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research. The report, commissioned by the Medical Research Council, Wellcome Trust and Academy of Medical Sciences, focused on the returns from UK investment into research in cardiovascular disease and mental health. It found that, for each
Full Post: New report shows the financial and social value of investing in medical research
The U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee today voted unanimously to recommend approval of Bausch & Lomb’s besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis.
The company has developed this broad-spectrum, anti-infective drop specifically for ophthalmic use.
All new chemical entities such as besifloxacin, a fluoroquinolone, must be reviewed by an FDA advisory committee as part of the approvals review process for new drug applications.
“We are encouraged by this morning’s committee discussion and vote, and look forward to continue working with the FDA to gain final approval,” said Flemming Ornskov, M.D., M.P.H., corporate vice president and global president, Pharmaceuticals, Bausch & Lomb. “Our intent remains to bring this innovative product to market, beginning in the U.S., in 2009.”
Allergan, Inc. has announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve LATISSE (bimatoprost solution 0.03%) as a treatment for hypotrichosis (or reduced amount of hair) of the eyelashes. If approved, LATISSE would be the first and only FDA-approved pharmaceutical
Full Post: FDA Advisory Committee Unanimously Recommends Approval of LATISSE™ (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
Daiichi Sankyo Company, Limited and Eli Lilly and Company has confirmed that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009. Prasugrel is an investigational antiplatelet agent for the treatment of patients with acute coronary syndromes (ACS) who
Full Post: FDA to review prasugrel for acute coronary syndromes
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of
Full Post: Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout
Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab. The application, filed by Centocor in late 2007, seeks approval to market ustekinumab as a subcutaneous biologic therapy for the treatment of adult patients with chronic moderate to severe plaque
Full Post: FDA issues complete response to biologics license application for ustekinumab
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy. The action letter includes proposed
Full Post: FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder